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Introduction {#bjo14712-sec-0008}
============

Unsafe termination of pregnancy (TOP) is the cause of substantial maternal mortality and morbidity worldwide. Factors such as legal restrictions and stigma aggravate estimates, but around 25% of all pregnancies are assessed to be terminated, and at least 22 800 preventable deaths occur globally each year.[1](#bjo14712-bib-0001){ref-type="ref"}, [2](#bjo14712-bib-0002){ref-type="ref"}

The scarcity of healthcare providers is one of many recognised barriers to safe TOP.[3](#bjo14712-bib-0003){ref-type="ref"} Legal regulations limiting TOP provision to specialist doctors and a reluctance to provide TOP among potential healthcare providers because of stigma and fear of reprisals are among reasons that providers of TOP, and especially medical TOP, are limited in higher as well as lower resource settings, even where TOP is legal.[4](#bjo14712-bib-0004){ref-type="ref"}, [5](#bjo14712-bib-0005){ref-type="ref"}, [6](#bjo14712-bib-0006){ref-type="ref"} Women\'s preference of providers influence their care‐seeking behaviour, and may therefore increase their risk of undergoing unsafe procedures.[7](#bjo14712-bib-0007){ref-type="ref"} Acceptability, womens\' ability to accept aspects of care, and satisfaction with services are particularily important in settings where women are at risk of unsafe TOP.[8](#bjo14712-bib-0008){ref-type="ref"}

Task shifting and sharing of medical services with trained non‐doctor providers has the potential to increase access and decrease unsafe TOP, and it\'s consequences. Previous reviews have found that non‐doctor provision of TOP is efficacious and safe, but those reviews included studies on surgical TOP and a limited number of studies on medical TOP.[9](#bjo14712-bib-0009){ref-type="ref"}, [10](#bjo14712-bib-0010){ref-type="ref"}, [11](#bjo14712-bib-0011){ref-type="ref"} The World Health Organization (WHO) has recently developed guidelines recommending that medical TOP and treatment for incomplete miscarriage in the first trimester using recommended clinical interventions (vacuum aspiration and medical TOP using mifepristone and misoprostol, or misoprostol alone, as well as medical treatment for incomplete miscarriage using misoprostol) can be managed by trained auxiliary nurse midwives, nurses, midwives, and associate clinicians.[12](#bjo14712-bib-0012){ref-type="ref"}, [13](#bjo14712-bib-0013){ref-type="ref"} Treatment for incomplete miscarriage with misoprostol is an acceptable alternative to surgical evacuation.[14](#bjo14712-bib-0014){ref-type="ref"} Medical methods are especially feasible in settings with limited healthcare facilities, but is often not offered because of legal restrictions and a lack of knowledge and training among existent providers.[15](#bjo14712-bib-0015){ref-type="ref"}, [16](#bjo14712-bib-0016){ref-type="ref"}

There is growing evidence supporting that provision of medical TOP and treatment of incomplete miscarriage by trained non‐doctor providers is as effective and safe as provision by doctors, as well as being cost‐effective.[17](#bjo14712-bib-0017){ref-type="ref"} The provision of either treatment involves similar skills in terms of eligibility assessment, counselling, administration of medication, and assessment of completion. This study aims to review the effectiveness, safety, and acceptability of non‐doctor provision of first‐trimester medical TOP, including medical treatment for incomplete miscarriage.

Methods {#bjo14712-sec-0009}
=======

Inclusion criteria {#bjo14712-sec-0010}
------------------

The criteria for considering studies for review were defined in terms of PICOs (participants, interventions, comparisons, outcomes, and study designs) questions. Participants were pregnant women seeking medical TOP through 12 weeks of gestation or medical treatment for incomplete miscarriage (including both miscarriage and TOP). The intervention was medical TOP or medical treatment of incomplete abortion provided by non‐doctor providers \[auxiliary nurse midwives (ANMs), nurses, midwives, non‐conventional therapies doctors or associate clinicians\]. Comparisons were medical TOP or medical treatment of incomplete miscarriage provided by non‐specialist and specialist doctors. The outcome measures were:

effectiveness, measured as complete TOP without need for additional surgical intervention following the procedure;safety, measured as serious adverse events (need for hospital admission, blood transfusion, or death);acceptability, measured as women\'s overall satisfaction with the provider or services provided, and whether women would recommend the same treatment or provider to a friend, or whether they would prefer the same type of provider in the case of a future termination of pregnancy.

Eligible study designs were randomised controlled trials (RCTs) and comparative observational studies, including cohort and case--control studies.

Search strategy {#bjo14712-sec-0011}
---------------

A search strategy was developed using relevant medical subject headings (MeSH) and free‐text words (tw) for each of the study components and adapted to all included databases. We combined search terms for provider types and TOP generally, as well as specific tasks associated with the process (Appendix [S1](#bjo14712-sup-0004){ref-type="supplementary-material"}). The databases PubMed, EMBASE, CINAHL, POPLINE, Global Index Medicus, Cochrane database, and ClinicalTrials.gov were searched from inception through July 2014 for all articles published in peer‐reviewed journals, and the search was updated using the same search strategy in April 2016. There were no time or language restrictions.

Data collection and analysis {#bjo14712-sec-0012}
----------------------------

Two authors (MD and SS) reviewed the titles and abstracts and, when necessary, the full article to identify studies that met the PICOs criteria. Reference lists from articles identified by the search, as well as other key reviews, were hand‐searched to identify additional papers. We also contacted investigators with continuing trials identified on ClinicalTrials.gov and other researchers in the field to seek information on unpublished or continuing studies that were unavailable through the electronic search.

We systematically and independently abstracted and summarised the evidence (MD and SS) using standard abstraction forms considering study characteristics, including design, participants, intervention, outcome, and assessment method. We (MD and SS) assessed the risk of bias in individual studies based on the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions.[18](#bjo14712-bib-0018){ref-type="ref"}

Results for our outcomes were pooled in meta‐analyses by one researcher (MSF) using [revman]{.smallcaps} 5.3 (2014).[19](#bjo14712-bib-0019){ref-type="ref"} The measures of effect were pooled risk ratios (RRs) of the outcomes. Data on the number of events and number of participants assigned to each treatment group were meta‐analysed using Mantel--Haenszel random‐effects models.[18](#bjo14712-bib-0018){ref-type="ref"} We performed intention to treat (ITT) and per protocol (PP) analysis, where possible. Two researchers (MSF and AF) independently assessed the overall certainty of the evidence using the GRADE (Grading of Recommendations‐Assessment, Development and Evaluation) system (GRADEpro Guideline Development Tool 2015). Five factors were considered: 1) study limitations, 2) inconsistency, 3) imprecision, 4) indirectness, and 5) publication bias to determine the certainty of the evidence for each outcome. The certainty of the evidence was classified in four groups ranging from very low (any estimate of effect is very uncertain) through low and moderate to high (further research is very unlikely to change the confidence in estimates).

This report is adapted from a review initiated as part of the evidence syntheses for the *WHO guideline on health worker roles in safe abortion care and post‐abortion contraception*, which considered different cadres of non‐doctor providers separately.[12](#bjo14712-bib-0012){ref-type="ref"} For the purpose of this paper, we synthesised research evidence for medical TOP provision by all cadres of non‐doctor providers compared with provision by doctors. This systematic review was conducted following the WHO principles for guideline development,[20](#bjo14712-bib-0020){ref-type="ref"} and national experts in the field were consulted at WHO regional meetings. The PRISMA (preferred reporting items for systematic reviews and meta‐analyses) criteria were also considered.

Funding {#bjo14712-sec-0013}
-------

SS\'s and KGD\'s work with the present substudy was supported financially by the Swedish research council (ref. no. K213‐54X‐14212‐12‐5) and the Stockholm City County/Karolinska Institutet (ALF). BG and MD were supported by WHO. MSF was funded by the Norwegian Agency for Development Cooperation (NORAD). The funding bodies had no influence on study design or conducting the study.

Results {#bjo14712-sec-0014}
=======

Search results {#bjo14712-sec-0015}
--------------

Our search yielded a total of 9425 citations, 8939 of which were unique. Studies were excluded after screening the title and abstract or the full‐text article (*n* = 60), based on study design, lacking a comparison group, or not assessing the outcomes of interest. Five reports from four RCTs,[21](#bjo14712-bib-0021){ref-type="ref"}, [22](#bjo14712-bib-0022){ref-type="ref"}, [23](#bjo14712-bib-0023){ref-type="ref"}, [24](#bjo14712-bib-0024){ref-type="ref"}, [25](#bjo14712-bib-0025){ref-type="ref"} and one report of a prospective cohort study,[26](#bjo14712-bib-0026){ref-type="ref"} met our inclusion criteria (Figure [S1](#bjo14712-sup-0001){ref-type="supplementary-material"}).

Characteristics of the included studies {#bjo14712-sec-0016}
---------------------------------------

Three articles reported from low‐income settings, in Uganda and Nepal,[21](#bjo14712-bib-0021){ref-type="ref"}, [22](#bjo14712-bib-0022){ref-type="ref"}, [23](#bjo14712-bib-0023){ref-type="ref"} one from a lower‐middle income setting, in India,[26](#bjo14712-bib-0026){ref-type="ref"} one from a higher middle income setting, in Mexico,[24](#bjo14712-bib-0024){ref-type="ref"} and one study was conducted in the high‐income setting of Sweden.[25](#bjo14712-bib-0025){ref-type="ref"}, [27](#bjo14712-bib-0027){ref-type="ref"} One RCT included ANMs and nurses,[21](#bjo14712-bib-0021){ref-type="ref"} one RCT included nurse‐midwives (NMWs),[25](#bjo14712-bib-0025){ref-type="ref"} and a third RCT included nurses,[24](#bjo14712-bib-0024){ref-type="ref"} all compared with doctors. The prospective cohort study from India reported on the provision of medical abortion by Ayurvedic doctors (non‐conventional therapies doctors in the Indian system of medicine) or nurses, compared with doctors.[26](#bjo14712-bib-0026){ref-type="ref"} The results from one RCT comparing midwife treatment of incomplete miscarriage with treatment by doctors were reported in two publications, covering effectiveness and safety,[22](#bjo14712-bib-0022){ref-type="ref"} and satisfaction and acceptability outcomes,[23](#bjo14712-bib-0023){ref-type="ref"} respectively.

The specific medical TOP or medical treatment of incomplete miscarriage regimens used differed across studies, but within each study all providers offered the same treatment regimens. Three RCTs,[21](#bjo14712-bib-0021){ref-type="ref"}, [24](#bjo14712-bib-0024){ref-type="ref"}, [25](#bjo14712-bib-0025){ref-type="ref"} and one prospective cohort study,[26](#bjo14712-bib-0026){ref-type="ref"} reported on treatment with combined mifepristone and misoprostol regimens for induced TOP with maximum gestational age of 63--70 days (mean 6.4--7.6 weeks of gestation). One RCT used 600 micrograms of oral misoprostol to treat incomplete miscarriage when uterine size was assessed to be below 12 weeks of gestation (mean 8.8 weeks of gestation) (Table [1](#bjo14712-tbl-0001){ref-type="table-wrap"}).[22](#bjo14712-bib-0022){ref-type="ref"}, [23](#bjo14712-bib-0023){ref-type="ref"} A summary of outcome data is presented in Table [S1](#bjo14712-sup-0002){ref-type="supplementary-material"}.

###### 

Characteristics of included studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, location                                                Study design, period                                                                                                                  Participatnts *n*, gestational age                                                                                        Intervention                                                                                                                                                                                                                                                                        Indication and medical regimen                                                                                                                                        Outcome, method, and time of assessment
  --------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Warriner, 2011\                                                 RCT, equivalence trial\                                                                                                               1104 women\                                                                                                               MLP *n* = 11 (nurses *n* = 8,\                                                                                                                                                                                                                                                      Induced TOP\                                                                                                                                                          Primary: complete TOP\
  Nepal\                                                          Apr 2009--Mar 2010\                                                                                                                   (MLP *n* = 552, doctors *n* = 552)\                                                                                       Aux. NMW *n* = 3)\                                                                                                                                                                                                                                                                  Mife: 200 milligram oral\                                                                                                                                             Secondary: case management decisions\
  Five district hospitals rural/peri‐urban area                   ITT and PP analysis\                                                                                                                  ≤63 days\                                                                                                                 Doctors *n* = 14 (ob/gyn *n *= 6; GP *n* = 3, BM/BS degree *n* = 5)                                                                                                                                                                                                                 Miso 800 microgram vag\                                                                                                                                               Records of serious adverse events (blood transfusion, hospitalisation)
                                                                                                                                                                                                        TOP                                                                                                                                                                                                                                                                                                                                                                                                           Follow‐up: day 10--14                                                                                                                                                 

  Kopp‐Kallner, 2014\                                             RCT, equivalence trial\                                                                                                               1180 women randomised (NMW *n* = 597; Doctor n=583)\                                                                      NMW *n* = 2 experienced in MA and contraceptive counselling\                                                                                                                                                                                                                        Induced TOP\                                                                                                                                                          Primary outcome: efficacy successful completion of TOP without need for vacuum aspiration\
  Sweden\                                                         Feb 2011--Jul 2012\                                                                                                                   ≤63 days by LMP\                                                                                                          Doctors *n* = 34 with months to years of training and experience\                                                                                                                                                                                                                   Day 1: 200 milligram mifepristone\                                                                                                                                    Secondary outcome: safety defined as no need for hospitalisation or blood transfusion and acceptability\
  Outpatient clinic                                               PP analysis\                                                                                                                          Mean GA\                                                                                                                  NMW theoretical and practical training in vaginal ultrasound\                                                                                                                                                                                                                       Oral\                                                                                                                                                                 Complication need for causal treatment at an unscheduled visit up to 6 weeks after MA\
                                                                  Clinical trials reg 01612923 NCT                                                                                                      45 days in both groups\                                                                                                   Doctors no additional training\                                                                                                                                                                                                                                                     Day 2--3: 800 microgram Misoprostol\                                                                                                                                  Efficacy and safety assessed by self‐administered questionnaires and medical records. Acceptability assessed through self‐administered questionnaires. Recorded need for second opinion and reason.\
                                                                                                                                                                                                        TOP                                                                                                                       Assigned provider medical history, clinical exam, ultrasound\                                                                                                                                                                                                                       Vaginally or bucally at home or in clinic\                                                                                                                            Contaceptive method prior to and after MA
                                                                                                                                                                                                                                                                                                                                  Intervention: Single NMW counselled, informed, examined, and treated woman\                                                                                                                                                                                                         Repeat misoprostol 400 microgram oral if no bleeding at 3 hours after dose 1\                                                                                         
                                                                                                                                                                                                                                                                                                                                  Standard: doctor counselling and clinical examination, additional information and medication provided by NMW not in study                                                                                                                                                           Follow up: U‐Hcg after approx. 3 weeks                                                                                                                                

  Olavarrieta, 2014\                                              RCT, non‐inferiority trial\                                                                                                           1017 women randomised (doctors *n* = 514; nurses *n* = 503); excluded nearly half for attempts at TOP prior to arrival\   Nurses *n* = 7, doctors *n* = 8\                                                                                                                                                                                                                                                    Induced TOP\                                                                                                                                                          To assess effectiveness, safety and acceptability of nurses' versus doctors provision of early medical TOP\
  Mexico city Ministry of Health\                                 Nov 2012--Jan 2013\                                                                                                                   GA \<70 days\                                                                                                             No previous experience with MA/only managed MA under supervision\                                                                                                                                                                                                                   Day 1: 200 milligram mifepristone oral\                                                                                                                               Complete TOP without surgical intervention. Checklist review of clinical symptoms and bleeding hx as well as results of abdominal ultrasound\
  two government TOP clinics, one hospital                        Computer‐generated randomisation\                                                                                                     Mean GA = 53 days (abdominal ultrasound)\                                                                                 Training 1.5 weeks for MA and 20 hours training in ultrasound\                                                                                                                                                                                                                      Day 2: 800 microgram misoprostol buccal\                                                                                                                              All adverse and serious adverse events were recorded\
                                                                  14‐question acceptability survey with acceptability score.\                                                                           TOP                                                                                                                       Eligibility screening nurse participating in study\                                                                                                                                                                                                                                 Follow‐up 7--15 days 800 microgram misoprostol if suspected continuing pregnancy or incomplete TOP. Then follow‐up after another 7--15 days                           14‐item satisfaction survey\
                                                                  ITT and PP analysis                                                                                                                                                                                                                                             Assigned provider: abdominal ultrasound for GA, gave instructions and counselling on post‐TOP contraception\                                                                                                                                                                                                                                                                                                                                              Contraceptive counselling/provision
                                                                                                                                                                                                                                                                                                                                  Follow‐up by assigned provider: clinical symtoms and abdominal ultrasound\                                                                                                                                                                                                                                                                                                                                                                                
                                                                                                                                                                                                                                                                                                                                  Satisfaction survey by study coordinator post TOP                                                                                                                                                                                                                                                                                                                                                                                                         

  Klingberg‐Allvin, 2015\                                         RCT, equivalence trial\                                                                                                               1010 randomised: midwife (*n* = 506); doctors (*n* = 504)\                                                                Midwives *n* = 29, doctors *n* = 13\                                                                                                                                                                                                                                                Incomplete TOP\                                                                                                                                                       Primary outcome: complete TOP without need for surgical intervention within 14--28 days of initial treatment assessed through physical and pelvic exam\
  UGANDA\                                                         Mar 2013--Jul 2014\                                                                                                                   PP analysis: 472 NMW and 483 doctors\                                                                                     Eligible participants worked at the maternal health section and involved in PAC; 5 days of training in PAC\                                                                                                                                                                         Day 1: misoprostol 600 microgram oral, clinic\                                                                                                                        Secondary outcomes: bleeding, pain, and unscheduled visits using symptom diary card and a visual analogue scale (VAS)
  Six primary health facilities in rural and peri‐urban regions   Computerised randomisation\                                                                                                           Mean GA 8.8 weeks\                                                                                                        Assigned provider: detailed information on bleeding and pain and abnormal symptoms and importance of seeking care, and contraceptive counselling. RA: eligibility screening and enrolment, measured primary and secondary outcomes at follow‐up visit (midwives not in study)       analgesic (ibuprofen or paracetamol) and oral antibiotics according to national guidelines\                                                                           
                                                                  Per protocol analysis\                                                                                                                Incomplete TOP                                                                                                                                                                                                                                                                                                                                                                                                Follow up after 14--28 days                                                                                                                                           
                                                                  CONSORT guidelines\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                  Clinical trials NCT01844024                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Cleeve et al. 2016\                                             RCT, equivalence trial\                                                                                                               1010 randomised: midwife (*n* = 506); doctors (*n* = 504)\                                                                Midwives *n* = 29**,** doctors *n* = 13\                                                                                                                                                                                                                                            Incomplete TOP\                                                                                                                                                       Primary outcome acceptability measured in expectations and satisfaction. Standardised questionnaires 14--28 days after treatment were used\
  UGANDA\                                                         Analysis of secondary outcomes\                                                                                                       PP analysis: NMW = 472, doctors = 483\                                                                                    Eligible participants worked at the maternal health section and involved in PAC; 5 days of training in PAC\                                                                                                                                                                         Misoprostol 600 microgram Oral\                                                                                                                                       Overall acceptability was regarded as a dependent variable and measures such as bleeding, pain, feeling calm were regarded as independent variables reflecting the woman\'s treatment experience
  Six primary health facilities in rural and peri‐urban regions   Mar 2013--Jul 2014\                                                                                                                   Mean GA 8.8 weeks\                                                                                                        Assigned provider: detailed information on bleeding and pain and abnormal symptoms and importance of seeking care, and contraceptive counselling. RA: eligibility screening and enrolment, and measured primary and secondary outcomes at follow‐up visit (midwives not in study)     (Day 1) with monitoring in clinic x4 hours\                                                                                                                         
                                                                  Computerised randomisation\                                                                                                           Incomplete TOP                                                                                                                                                                                                                                                                                                                                                                                                Analgesics (ibuprofen or paracetamol) and oral antibiotics according to national guidelines                                                                           
                                                                  Clinical trials NCT01844024                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Jejeeboy, 2012\                                                 Prospective\                                                                                                                          1414 women assessed by pelvic exam\                                                                                       Allopathic doctors *n* = 10\                                                                                                                                                                                                                                                        Induced TOP\                                                                                                                                                          Complete TOP measured as no need for subsequent surgical intervention (day 15--21). Complication rates, blood transfusion, and hospitalisation\
  INDIA\                                                          Cohort\                                                                                                                               1225 eligible\                                                                                                            Ayurvedic doctors *n* = 10\                                                                                                                                                                                                                                                         Medical eligibility determined by history and haemoglobin testing. GA determination by BME (by provider and verifier) and urine pregnancy test; no ultrasound used\   Secondary outcomes: correct eligibility assessment and assessment of complete TOP compared with verifier\
  five clinics operated by NGO in four urban areas\               Dec 2008--May 2010\                                                                                                                   Ayurvedic (*n* = 404)\                                                                                                    Nurses *n* = 10\                                                                                                                                                                                                                                                                    Day 1: 200 milligram mifepristone\                                                                                                                                    Acceptability: overall satisfaction with services and should they undergo procedure with same type of provider if needed. Recorded at exit interviews\
                                                                  Providers rotated across sites and remained for around 6 weeks or 35--40 med ab. Clients unaware of which provider at which clinic\   Nurses (*n* = 416)\                                                                                                       No prior experiencein MA, BME, or assessed GA\                                                                                                                                                                                                                                      Oral, clinic\                                                                                                                                                         All provided post‐TOP contraception including referral for tubal ligation or IUD insertion
                                                                  Two‐sided equivalence design                                                                                                          Allopathic (*n* = 405)\                                                                                                   10 days of training and field observation of a minimum of ten cases\                                                                                                                                                                                                                Day 3: 400 microgram misoprostol\                                                                                                                                     
                                                                                                                                                                                                        \<8 weeks\                                                                                                                Provider gave information about own medical background, training, medical TOP procedure, side effects, post‐TOP contraception\                                                                                                                                                      Oral, clinic\                                                                                                                                                         
                                                                                                                                                                                                        Recruited women lived within 1 hour of facility\                                                                          Verifier assess eligibility and TOP completeness, prescription of drugs, management of serious adverse events\                                                                                                                                                                      Follow‐up: day 15 and if needed on day 21\                                                                                                                            
                                                                                                                                                                                                        TOP                                                                                                                       Exit interview by research coordinator recorded satisfaction                                                                                                                                                                                                                        Routine antibiotics                                                                                                                                                   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BME, bimanual exam; CRL, crown--rump length; GA, gestational age; GSD, gestational sac diameter; Hgb haemoglobin level; IIT, intention to treat; LARC, long‐acting reversible contraception; LMP, last menstrual period; MA, medical abortion; MLP, mid‐level provider; NMW, nurse midwife; PAC, post‐abortion care; PP, per protocol; RA, research assistant; TOP, termination of pregnancy.
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Outcome measures {#bjo14712-sec-0017}
----------------

### Effectiveness {#bjo14712-sec-0018}

All four included RCTs, and one prospective cohort study,[26](#bjo14712-bib-0026){ref-type="ref"} defined effectiveness of medical TOP as complete TOP without the need for vacuum aspiration. Clinical assessment was the primary method for determining TOP completion. In addition, one RCT reported on routine use of low‐sensitivity urine pregnancy testing,[25](#bjo14712-bib-0025){ref-type="ref"} and one study used abdominal ultrasound to confirm gestational length and TOP completion.[24](#bjo14712-bib-0024){ref-type="ref"}

In our ITT analysis for the outcome of effectiveness, three RCTs provided enough information to be included in the analysis.[21](#bjo14712-bib-0021){ref-type="ref"}, [22](#bjo14712-bib-0022){ref-type="ref"}, [24](#bjo14712-bib-0024){ref-type="ref"} Even though Klingberg‐Allvin et al.[22](#bjo14712-bib-0022){ref-type="ref"} reported results PP, we consider the same population number in both the ITT and PP analysis from this study, as the population was only marginally different in the two groups. Our meta‐analysis show that effectiveness, measured as the complete TOP rate, is probably equivalent between the provider groups, as the effect estimate (RR 1.00, 95% CI 0.99--1.01) show no clinically significant difference with very narrow confidence intervals (Figure [1](#bjo14712-fig-0001){ref-type="fig"}, analysis A). Subgroup analyses shows that complete TOP rates may be similar between provider groups whether women are seeking medical TOP or medical treatment of incomplete TOP. The validity of the evidence is moderate (Table [2](#bjo14712-tbl-0002){ref-type="table-wrap"}). These findings were verified by the PP analysis carried out with all four RCTs reporting on this outcome (RR 1.00, 95% CI 0.99--1.02) (Figure [1](#bjo14712-fig-0001){ref-type="fig"}, analysis B).

![Meta‐analysis of effectiveness.](BJO-124-1928-g001){#bjo14712-fig-0001}

###### 

Certainty of evidence (GRADE)

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Non‐doctors compared with doctors providing medical termination of pregnancy                                                                                                                                                                                                                                                                                                                                                    
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- ------------------- ---------------- --------------- ----------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Effectiveness**\                                                                                                                                                                                               970 per 1 000   **970 per 1000**\   **RR 1.00**\     2871\           ⨁⨁⨁◯\                                                                                                                                     **Interpretation:**\
  Complete TOP without surgical intervention\                                                                                                                                                                                        (961--980)          (0.99--1.01)     (3 RCTs)      MODERATE[b](#bjo14712-note-0003){ref-type="fn"}                                                                                           There is probably little or no difference in the effectiveness (complete TOP without surgical intervention) of medical termination of pregnancy among women treated and followed up by non‐ doctors versus doctors
  ITT analysis                                                                                                                                                                                                                                                                                                                                                                                                                    

  **Effectiveness**\                                                                                                                                                                                               972 per 1 000   **972 per 1000**\   **RR 1.00**\     3670\           ⨁⨁⨁◯\                                                                                                                                     **Interpretation:**\
  Complete TOP without surgical intervention\                                                                                                                                                                                        (963--992)          (0.99--1.02)     (4 RCTs)      MODERATE[b](#bjo14712-note-0003){ref-type="fn"}                                                                                           There is probably little or no difference in the effectiveness (complete TOP without surgical intervention) of medical termination of pregnancy among women treated and followed up by non‐ doctors versus doctors
   \                                                                                                                                                                                                                                                                                                                                                                                                                              
  PP analysis                                                                                                                                                                                                                                                                                                                                                                                                                     

  **Safety**\                                                                                                                                                                                                      1 per 1 000     **0 per 1000**\     not estimable    2915\           --                                                                                                                                        **Interpretation:**\
  Serious adverse events (need for hospital admission, blood transfusion, or death)                                                                                                                                                  (0--0)                               (3 studies)                                                                                                                                             We are uncertain of the effect estimate because there are very few serious events and we can thus not generalise about how different or similar the effect of being treated and followed up by non‐doctors versus doctors is

  **Acceptability/satisfaction**\                                                                                                                                                                                  985 per 1 000   **985 per 1000**\   **RR 1.00**\     1842\           ⨁⨁⨁◯\                                                                                                                                     **Interpretation:**\
  Would you recommend to a friend?\                                                                                                                                                                                                  (975--994)          (0.99--1.01)     (2 RCTs)      MODERATE[b](#bjo14712-note-0003){ref-type="fn"}                                                                                           There is probably little or no difference in the acceptability/satisfaction (would recommend to a friend) of medical termination of pregnancy among women treated and followed up by non‐doctors versus doctors
   \                                                                                                                                                                                                                                                                                                                                                                                                                              
  ITT analysis                                                                                                                                                                                                                                                                                                                                                                                                                    

  **Acceptability/satisfaction**\                                                                                                                                                                                  797 per 1 000   **948 per 1000**\   **RR 1.19**\     2021\           ⨁◯◯◯\                                                                                                                                     **Interpretation:**\
  Would you recommend to a friend?\                                                                                                                                                                                                  (406--1 000)        (0.51--2.75)     (2 RCTs)      VERY LOW[b](#bjo14712-note-0003){ref-type="fn"} ^,^ [c](#bjo14712-note-0004){ref-type="fn"} ^,^ [d](#bjo14712-note-0005){ref-type="fn"}   We are uncertain of the effect estimate because the validity of the evidence has been assed as very low
   \                                                                                                                                                                                                                                                                                                                                                                                                                              
  PP analysis                                                                                                                                                                                                                                                                                                                                                                                                                     

  **Acceptability/satisfaction**\                                                                                                                                                                                  969 per 1 000   **969 per 1000**\   **RR 1.00**\     1838\           ⨁⨁⨁◯\                                                                                                                                     **Interpretation:**\
  Overall satisfaction\                                                                                                                                                                                                              (969--979)          (1.00--1.01)     (2 RCTs)      MODERATE[b](#bjo14712-note-0003){ref-type="fn"}                                                                                           There is probably little or no difference in the acceptability/satisfaction (overall satisfaction) of medical termination of pregnancy among women treated and followed up by non‐doctors versus doctors
   \                                                                                                                                                                                                                                                                                                                                                                                                                              
  ITT analysis                                                                                                                                                                                                                                                                                                                                                                                                                    

  **GRADE working group grades of evidence**                                                                                                                                                                                                                                                                                                                                                                                      

  **High quality:** we are very confident that the true effect lies close to that of the estimate of the effect                                                                                                                                                                                                                                                                                                                   

  **Moderate quality:** we are moderately confident in the effect estimate -- the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different                                                                                                                                                                                                                  

  **Low quality**: our confidence in the effect estimate is limited -- the true effect may be substantially different from the estimate of the effect                                                                                                                                                                                                                                                                             

  **Very low quality:** we have very little confidence in the effect estimate -- the true effect is likely to be substantially different from the estimate of effect.                                                                                                                                                                                                                                                             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

Overall unclear risk of bias in included studies.

Very high heterogeneity.

Somewhat broad 95% CI that crosses the line of no effect.

John Wiley & Sons, Ltd

### Safety {#bjo14712-sec-0019}

Across all studies, only one serious adverse event was recorded: one woman was hospitalised for heavy bleeding and underwent surgical TOP without further complications (Table [S1](#bjo14712-sup-0002){ref-type="supplementary-material"}).[24](#bjo14712-bib-0024){ref-type="ref"} As a result of rarity of recorded events, meta‐analysis and assessment of validity of the evidence was not performed; studies were not powered to detect differences in safety according to provider. Only one RCT clearly defined safety outcomes in the trial: need for hospitalisation or blood transfusion.[25](#bjo14712-bib-0025){ref-type="ref"} Another RCT stated that all adverse and serious adverse events were recorded and analysed to allow for safety reporting, but did not specify which events were considered.[24](#bjo14712-bib-0024){ref-type="ref"} The prospective cohort study defined serious adverse events as haemorrhage requiring blood transfusion and/or need for hospitalisation, but did not clearly state what measures were considered when reporting on safety. This study reported that no women had serious complications or required blood transfusion or hospitalisation.[26](#bjo14712-bib-0026){ref-type="ref"} The rest of the RCTs did not make a clear definition of serious adverse events.

### Acceptability {#bjo14712-sec-0020}

Three RCTs provided enough information to be included in the ITT analyses for the outcome of acceptability/satisfaction with treatment and/or service outcomes.[23](#bjo14712-bib-0023){ref-type="ref"}, [24](#bjo14712-bib-0024){ref-type="ref"}, [25](#bjo14712-bib-0025){ref-type="ref"} Cleeve et al.[23](#bjo14712-bib-0023){ref-type="ref"} reported PP analysis only, but we report the same population number in both ITT and PP analyses from this study because the population was only marginally different in the two cases. The meta‐analyses report on women\'s acceptance of the allocated treatment and/or provider in terms of whether women would recommend the same treatment or provider to a friend, or whether they would prefer the same type of provider in case of a future TOP. These statements were considered to similarly assess the woman\'s acceptance of the procedure/provider, as it is unlikely that you would recommend a treatment to a friend that you would not undergo yourself. Our meta‐analysis show that the result is probably equivalent between provider groups, as the effect estimate shows no clinically significant difference, with a narrow confidence interval (RR 1.00, 95% CI 0.99--1.01; Figure [2](#bjo14712-fig-0002){ref-type="fig"}, analysis A). The validity of the evidence is moderate (Table [2](#bjo14712-tbl-0002){ref-type="table-wrap"}). We are uncertain if the PP analysis can verify the findings by the ITT analysis for this outcome because the validity of the evidence was assessed as very low (Figure [2](#bjo14712-fig-0002){ref-type="fig"}, analysis B).

![Meta‐analysis of acceptability.](BJO-124-1928-g002){#bjo14712-fig-0002}

Two RCTs reported on overall satisfaction.[23](#bjo14712-bib-0023){ref-type="ref"}, [24](#bjo14712-bib-0024){ref-type="ref"} Our ITT meta‐analysis show that women are probably equally satisfied 'all in all' with the provider, regardless of provider allocation (RR 1.00, 95% CI 1.00--1.01; Figure [2](#bjo14712-fig-0002){ref-type="fig"}, analysis C). The validity of evidence is moderate (Table [2](#bjo14712-tbl-0002){ref-type="table-wrap"}). As there was only one study with enough information provided,[23](#bjo14712-bib-0023){ref-type="ref"} we did not perform a PP analysis for this outcome, also this study was already included in the ITT analysis and the population was only marginally different in the two cases of analyses provided by the study authors.

The prospective cohort study also reported on satisfaction. At recruitment, a 0.5% refusal rate of the assigned provider was registered; however, at the time of exit interviews satisfaction with the assigned provider was high (98--99%). Almost all women in this study stated that they would undergo treatment from the same provider type again.[26](#bjo14712-bib-0026){ref-type="ref"} Two articles did not report any outcomes on acceptability or satisfaction.[21](#bjo14712-bib-0021){ref-type="ref"}, [22](#bjo14712-bib-0022){ref-type="ref"}

Discussion {#bjo14712-sec-0021}
==========

Quality of evidence {#bjo14712-sec-0022}
-------------------

An assessment of the risk of bias in the RCTs showed that there was no selection bias (sequence generation and allocation concealment) in the included RCTs. There was risk of performance bias as well as detection bias in all studies, as participants were not blinded to provider type, and there was no report of the blinding of outcome assessors. Attrition bias, or incomplete outcome data, was adequately addressed in four reports (three RCTs).[21](#bjo14712-bib-0021){ref-type="ref"}, [22](#bjo14712-bib-0022){ref-type="ref"}, [23](#bjo14712-bib-0023){ref-type="ref"}, [24](#bjo14712-bib-0024){ref-type="ref"} Whether there was selective reporting bias (analyses with statistically significant results are more likely to be reported than non‐significant results) was unclear for all RCTs (Table [S2](#bjo14712-sup-0003){ref-type="supplementary-material"}A). Risk of bias in the included prospective cohort study was found to be low (Table [S2](#bjo14712-sup-0003){ref-type="supplementary-material"}B).[26](#bjo14712-bib-0026){ref-type="ref"}

The validity of the evidence was assessed using the GRADE tool and ranged from very low to moderate (Table [2](#bjo14712-tbl-0002){ref-type="table-wrap"}).[28](#bjo14712-bib-0028){ref-type="ref"} For the outcomes where we assessed the quality of evidence as moderate, the main reason for downgrading was the unclear risk of bias in the included studies. The downgrading of the outcome where the quality of evidence was assessed as very low was for unclear risk of bias of included studies, very high heterogeneity, and imprecision (wide 95% CI of the effect estimate that crossed the line of no effect).

Main findings {#bjo14712-sec-0023}
-------------

We conclude that medical TOP and medical treatment of incomplete miscarriage performed by trained non‐doctor providers in the first trimester is probably as effective as treatment provided by doctors. We also conclude that women are probably equally satisfied with their provider regardless of who treats or manages their medical TOP.

Strengths and limitations {#bjo14712-sec-0024}
-------------------------

Despite the limited number of included studies, this is the largest systematic review of the provision of first‐trimester medical TOP by non‐doctor providers (ANMs, nurses, midwives, and non‐conventional therapies doctors), compared with doctors, and also the first to include the medical management of incomplete miscarriage. In addition, this is the first systematic review to report on women\'s acceptance of provider and services, and women\'s overall acceptance in terms of satisfaction with medical treatment for early TOP and incomplete miscarriage.

The generalisability of our findings may be low. Included studies were conducted in diverse settings and evaluated treatment of different populations of women (total *n* = 5823) from Nepal, Sweden, Mexico, Uganda, and India. The number of included providers varied between studies (non‐doctors, *n* = 69; doctors, *n* = 79), and the variability in training and prior professional experience was high. Although medical TOP is considered a relatively safe procedure, the included studies were not powered to report on significant differences regarding serious adverse events. We can therefore not conclude whether the safety is equal, higher, or lower between the two groups of medical TOP providers. Also, the definitions of adverse events, serious adverse events, and the measurement of safety were unclear in several studies.

Interpretation {#bjo14712-sec-0025}
--------------

Our findings on effectiveness, defined as complete TOP without surgical intervention, when non‐doctors provided medical TOP are consistent with findings of previously published systematic reviews.[9](#bjo14712-bib-0009){ref-type="ref"}, [10](#bjo14712-bib-0010){ref-type="ref"}, [11](#bjo14712-bib-0011){ref-type="ref"} The previous reviews conclude that the provision of medical TOP and medical treatment for incomplete miscarriage is as effective and safe when provided by non‐doctors as when provided by doctors; however, these reviews were broader in scope and evaluated non‐doctor provision of medical TOP in addition to surgical TOP. Our review is more comprehensive in its focus on the provision of medical TOP and medical treatment of incomplete miscarriage, including women\'s acceptance of the provider and services, and more and newer studies are included.

We defined the safety outcome as serious adverse events and concluded that the included studies were not powered to detect serious adverse events. Although all included studies reported on safety, the definitions and distinctions between serious adverse events, adverse events, and minor common complications were not clear in several studies. Although more events need to be reported to make a robust statistical generalisation about the influence of provider type on the likelihood of serious adverse events, the rarity of these events overall is very reassuring. Medical TOP in the first trimester using mifepristone and misoprostol is well established as an effective and safe method for TOP, and is feasible in different settings,[13](#bjo14712-bib-0013){ref-type="ref"} with a number of previous studies reporting high rates of complete TOP and very few serious adverse events.[29](#bjo14712-bib-0029){ref-type="ref"} We also conclude that standardised approaches to defining and reporting serious adverse events in subsequent studies would further strengthen our conclusions.

We found that women\'s acceptance of treatment and management of medical TOP or incomplete miscarriage is probably equally high between those provided by doctors versus non‐doctors. Furthermore, women probably equally prefer the same provider if they should need another TOP. Few previous studies and no systematic reviews have examined women\'s satisfaction with procedure and provider when seeking treatment for TOP and incomplete miscarriage. If women find the available procedures and providers acceptable, the likelihood that they will seek safe TOP providers when needed increases.[8](#bjo14712-bib-0008){ref-type="ref"}

We hypothesise that if we increase the numbers of facilities where non‐doctors are able to provide medical treatment for TOP, this can increase access to safe TOP and medical treatment of incomplete miscarriage. Provision by non‐doctor providers in a variety of facility‐based settings as part of routine care does not only increase access to care, but also helps de‐medicalise and normalise TOP services, which reduces stigma and augments women\'s care seeking, thereby preventing any delay to treatment.

Conclusion {#bjo14712-sec-0026}
==========

In this systematic review, we establish further support for non‐doctor provision of medical TOP and medical treatment of incomplete miscarriage. The effectiveness of treatment is probably similar regardless of whether it is provided by a non‐doctor provider or by a doctor (moderate validity of the evidence). Moreover, women\'s overall acceptance of their provider is probably similar regardless of allocation (very low to moderate validity of the evidence). The effect on safety is uncertain as our outcome measure, serious adverse event, is rare and the studies are not powered to allow for a generalisation about the effect treatment by the non‐doctors versus doctors have on safety. These findings are important for the successful implementation of non‐doctor provision of TOP care, and stresses the necessity to scale‐up such provision as soon as possible to increase access to safe TOP care.
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